{"id":965891,"date":"2026-05-21T09:03:24","date_gmt":"2026-05-21T13:03:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/hims-hers-brings-first-time-access-to-generic-semaglutide-to-canada\/"},"modified":"2026-05-21T09:03:24","modified_gmt":"2026-05-21T13:03:24","slug":"hims-hers-brings-first-time-access-to-generic-semaglutide-to-canada","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/hims-hers-brings-first-time-access-to-generic-semaglutide-to-canada\/","title":{"rendered":"Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada"},"content":{"rendered":"

<\/p>\n

Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada<\/b><\/p>\n

Personalised treatment plans pair medication with unlimited Care Team support, nutrition and lifestyle guidance, and Canadian medical expertise, starting at $149\/month<\/i><\/p>\n

TORONTO–(BUSINESS WIRE<\/a>)–
\nHims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform for eligible customers in Canada. This makes affordable GLP-1 treatment accessible to Canadians for whom cost has long been a barrier to treatment. For eligible customers, personalised treatment plans are available starting at $149\/month CAD.<\/p>\n

This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20260520762631\/en\/<\/a><\/p>\n

\"Personalised<\/p>\n

Personalised treatment plans pair medication with unlimited Care Team support, nutrition and lifestyle guidance, and Canadian medical expertise, starting at $149\/month<\/p>\n<\/div>\n

\nGLP-1 treatments have transformed obesity and metabolic health, with their significance extending well beyond weight alone. Nearly two-thirds of Canadian adults<\/a> are overweight or living with obesity, but cost has remained a significant barrier to access the treatment they need. Health Canada’s authorization of generic semaglutide marks a turning point, not just for Hims & Hers customers, but for the country’s broader healthcare landscape. This will help create a more dynamic GLP-1 market. As more providers offer access to affordable options, prices fall across the board, expanding access for patients regardless of where they seek care.<\/p>\n

\nThrough Hims & Hers, eligible customers in Canada will have access to personalised care plans that may include GLP-1 options, alongside unlimited and ongoing Care Team access and evidence-informed resources built around nutrition, movement, and sleep, all designed to support sustainable, lasting health habits. All Canadian customers are connected with Canadian providers who understand the healthcare landscape they\u2019re navigating and bring the local expertise and clinical rigour this kind of care demands.<\/p>\n

\n“Generics have always played a critical role in expanding access to medicines that change lives,\u201d said Dr. Sandy Van, Obesity Medicine Specialist and Chief Medical Officer, Hims & Hers Canada. \u201cToday marks a turning point: more choice, lower costs, and a genuine commitment to care built around the whole patient. Every Canadian deserves access to the treatment that’s right for them, regardless of what they can afford.”<\/p>\n

\n“Canada has a strong health system, and we are committed to helping support and strengthen it,” said Austin Kouri, General Manager, Hims & Hers Canada. “Bringing generic semaglutide to market means more Canadians have a real, affordable path to treatment. When patients have options and costs come down, everyone benefits. That’s exactly the kind of impact we’re here to create.”<\/p>\n

\nHims & Hers is committed to putting the right tools, the right providers, and the right support into the hands of Canadians who are ready to take control of their health.<\/p>\n

Generic semaglutide is authorized for sale by Health Canada for the management of Type 2 diabetes. It may be prescribed off-label for weight management in a licensed healthcare provider’s sole clinical judgment. Hims & Hers Canada Inc. does not currently offer access to treatment services for Type 2 diabetes.<\/b><\/p>\n

About Hims & Hers Health, Inc.<\/b><\/p>\n

\nHims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That\u2019s why we\u2019re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges\u2014and innovates on their solutions\u2014to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.ca<\/a> and www.forhers.ca<\/a>.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260520762631\/en\/<\/a><\/span><\/p>\n

Press Contact
\n<\/b>
Susan Cadrecha
\n
press@forhims.com<\/a><\/p>\n

KEYWORDS:<\/b> North America Canada<\/p>\n

INDUSTRY KEYWORDS:<\/b> Online Retail Retail Health Diabetes Fitness & Nutrition Pharmaceutical<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n\n\n\n
Photo<\/b><\/font><\/td>\n<\/tr>\n
\"Photo\"<\/td>\n<\/tr>\n
Personalised treatment plans pair medication with unlimited Care Team support, nutrition and lifestyle guidance, and Canadian medical expertise, starting at $149\/month<\/font><\/td>\n<\/tr>\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada Personalised treatment plans pair medication with unlimited Care Team support, nutrition and lifestyle guidance, and Canadian medical expertise, starting at $149\/month TORONTO–(BUSINESS WIRE)– Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform for eligible customers in Canada. This makes affordable GLP-1 treatment accessible to Canadians for whom cost has long been a barrier to treatment. For eligible customers, personalised treatment plans are available starting at $149\/month CAD. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20260520762631\/en\/ Personalised treatment plans pair medication with unlimited Care Team support, nutrition and lifestyle guidance, and Canadian medical … <\/p>\n

Continue reading “Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-965891","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nHims & Hers Brings First-Time Access to Generic Semaglutide to Canada - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hims-hers-brings-first-time-access-to-generic-semaglutide-to-canada\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada Personalised treatment plans pair medication with unlimited Care Team support, nutrition and lifestyle guidance, and Canadian medical expertise, starting at $149\/month TORONTO–(BUSINESS WIRE)– Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform for eligible customers in Canada. This makes affordable GLP-1 treatment accessible to Canadians for whom cost has long been a barrier to treatment. For eligible customers, personalised treatment plans are available starting at $149\/month CAD. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20260520762631\/en\/ Personalised treatment plans pair medication with unlimited Care Team support, nutrition and lifestyle guidance, and Canadian medical … Continue reading "Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/hims-hers-brings-first-time-access-to-generic-semaglutide-to-canada\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-21T13:03:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260520762631\/en\/2811798\/4\/26Q2_canada-sema_newsroom_businesswire.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hims-hers-brings-first-time-access-to-generic-semaglutide-to-canada\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hims-hers-brings-first-time-access-to-generic-semaglutide-to-canada\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada\",\"datePublished\":\"2026-05-21T13:03:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hims-hers-brings-first-time-access-to-generic-semaglutide-to-canada\\\/\"},\"wordCount\":693,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hims-hers-brings-first-time-access-to-generic-semaglutide-to-canada\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260520762631\\\/en\\\/2811798\\\/4\\\/26Q2_canada-sema_newsroom_businesswire.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hims-hers-brings-first-time-access-to-generic-semaglutide-to-canada\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hims-hers-brings-first-time-access-to-generic-semaglutide-to-canada\\\/\",\"name\":\"Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hims-hers-brings-first-time-access-to-generic-semaglutide-to-canada\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hims-hers-brings-first-time-access-to-generic-semaglutide-to-canada\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260520762631\\\/en\\\/2811798\\\/4\\\/26Q2_canada-sema_newsroom_businesswire.jpg\",\"datePublished\":\"2026-05-21T13:03:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hims-hers-brings-first-time-access-to-generic-semaglutide-to-canada\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hims-hers-brings-first-time-access-to-generic-semaglutide-to-canada\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hims-hers-brings-first-time-access-to-generic-semaglutide-to-canada\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260520762631\\\/en\\\/2811798\\\/4\\\/26Q2_canada-sema_newsroom_businesswire.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260520762631\\\/en\\\/2811798\\\/4\\\/26Q2_canada-sema_newsroom_businesswire.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hims-hers-brings-first-time-access-to-generic-semaglutide-to-canada\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/hims-hers-brings-first-time-access-to-generic-semaglutide-to-canada\/","og_locale":"en_US","og_type":"article","og_title":"Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada - Market Newsdesk","og_description":"Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada Personalised treatment plans pair medication with unlimited Care Team support, nutrition and lifestyle guidance, and Canadian medical expertise, starting at $149\/month TORONTO–(BUSINESS WIRE)– Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform for eligible customers in Canada. This makes affordable GLP-1 treatment accessible to Canadians for whom cost has long been a barrier to treatment. For eligible customers, personalised treatment plans are available starting at $149\/month CAD. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20260520762631\/en\/ Personalised treatment plans pair medication with unlimited Care Team support, nutrition and lifestyle guidance, and Canadian medical … Continue reading \"Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/hims-hers-brings-first-time-access-to-generic-semaglutide-to-canada\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-21T13:03:24+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260520762631\/en\/2811798\/4\/26Q2_canada-sema_newsroom_businesswire.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hims-hers-brings-first-time-access-to-generic-semaglutide-to-canada\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hims-hers-brings-first-time-access-to-generic-semaglutide-to-canada\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada","datePublished":"2026-05-21T13:03:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hims-hers-brings-first-time-access-to-generic-semaglutide-to-canada\/"},"wordCount":693,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hims-hers-brings-first-time-access-to-generic-semaglutide-to-canada\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260520762631\/en\/2811798\/4\/26Q2_canada-sema_newsroom_businesswire.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hims-hers-brings-first-time-access-to-generic-semaglutide-to-canada\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/hims-hers-brings-first-time-access-to-generic-semaglutide-to-canada\/","name":"Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hims-hers-brings-first-time-access-to-generic-semaglutide-to-canada\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hims-hers-brings-first-time-access-to-generic-semaglutide-to-canada\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260520762631\/en\/2811798\/4\/26Q2_canada-sema_newsroom_businesswire.jpg","datePublished":"2026-05-21T13:03:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hims-hers-brings-first-time-access-to-generic-semaglutide-to-canada\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/hims-hers-brings-first-time-access-to-generic-semaglutide-to-canada\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hims-hers-brings-first-time-access-to-generic-semaglutide-to-canada\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260520762631\/en\/2811798\/4\/26Q2_canada-sema_newsroom_businesswire.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260520762631\/en\/2811798\/4\/26Q2_canada-sema_newsroom_businesswire.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hims-hers-brings-first-time-access-to-generic-semaglutide-to-canada\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/965891","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=965891"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/965891\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=965891"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=965891"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=965891"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}